GRCE — Grace Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1444192 ·
Last close
$2.36
Market Cap
$36.52M
52W High
$5.18
52W Low
$1.79
ADV30
878,534
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | — | -2,449,000 | -2,315,000 | 68,488,000 | 18,672,000 | 3,596,000 |
| Sep 2025 | 0 | — | -2,529,000 | -938,000 | 66,576,000 | 16,862,000 | 3,758,000 |
| Jun 2025 | 0 | — | -3,090,000 | -3,362,000 | 69,805,000 | 20,005,000 | 6,255,000 |
| Mar 2025 | 0 | — | -3,183,000 | 636,000 | 71,993,000 | 22,133,000 | 5,383,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,128,000
Investing CF
$0
Financing CF
$17,745,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.77
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-227,302,000
Inventory
—
Receivables
$20,000
ST Investments
$15,000
EBIT TTM
$-11,251,000
Pretax Income TTM
$-6,997,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Mar 2025 | 0 | -16,679,000 | -9,568,000 | 71,993,000 | 5,383,000 | — | -14,904,000 |
| Mar 2024 | 0 | -11,367,000 | -12,853,000 | 73,300,000 | 11,557,000 | — | -12,333,000 |
| Mar 2023 | 0 | -18,247,000 | -42,429,000 | 79,123,000 | 11,168,000 | — | -15,913,000 |
| Mar 2022 | 0 | -15,340,000 | -9,819,000 | 128,620,000 | 20,350,000 | — | -17,234,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.69
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ATNM | Actinium Pharmaceuticals, Inc. | $36.39M | $1.16 | — |
| RADX | Radiopharm Theranostics Ltd | $36.34M | $4.61 | — |
| VERU | VERU INC. | $37.08M | $2.31 | — |
| LITS | Lite Strategy, Inc. | $35.73M | $1.05 | — |
| SDEV | Stablecoin Development Corp | $35.52M | $1.31 | — |
News headlines (Yahoo Finance, 1h cache)
Sector Update: Health Care Stocks Edge Lower Late Afternoon
2026-04-23 19:51 · Yahoo
Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104
2026-04-23 17:13 · Yahoo
Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026
2026-04-14 12:00 · Yahoo
We're Not Very Worried About Grace Therapeutics' (NASDAQ:GRCE) Cash Burn Rate
2026-04-04 13:52 · Yahoo
Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences
2026-03-19 12:00 · Yahoo
Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
2026-02-25 13:00 · Yahoo
Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update
2026-02-12 13:00 · Yahoo
Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference
2025-11-17 13:00 · Yahoo
Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update
2025-11-13 13:00 · Yahoo
Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting
2025-11-11 13:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.